FDA-Approved Essilor Stellest Lenses to Slow Myopia Progression in Children

Overview

The FDA has approved Essilor Stellest lenses for children aged 6 to 12 to slow the progression of myopia. Clinical data show a 70% reduction in myopia progression and a 50% reduction in eye elongation over two years.

Background

Myopia, or nearsightedness, is increasingly common among children, with 30% to 40% affected by high school in the U.S. It results in difficulty seeing distant objects clearly and is linked to increased near work and screen time. Progressive myopia can lead to serious eye complications such as retinal detachment, cataracts, and glaucoma. Until recently, treatment options were limited to corrective lenses without addressing progression.

Data Highlights

Key Findings

• Essilor Stellest lenses use 11 concentric rings with raised dots to refocus light and slow eye elongation.
• FDA approval was based on company data demonstrating a 70% reduction in myopia progression in children aged 6-12 over two years.
• Children wearing the lenses showed a 50% reduction in axial eye lengthening after two years.
• The lenses offer a non-contact lens alternative preferred by many parents and physicians.
• Side effects were minimal, with some children reporting visual disturbances like halos.
• Ongoing U.S. studies aim to confirm efficacy in diverse populations.

Clinical Implications

Essilor Stellest lenses provide a promising FDA-approved option to slow myopia progression in young children, potentially reducing future risks of severe eye disease. Clinicians should consider these lenses for eligible pediatric patients, especially those for whom contact lenses are not suitable. Monitoring for visual disturbances and further research in U.S. populations will guide broader adoption.

Conclusion

The introduction of Essilor Stellest lenses marks a significant advancement in managing pediatric myopia by slowing its progression and associated eye elongation. This innovation may help reduce long-term vision complications and improve quality of life for affected children.

References

1. Associated Press 2023 -- FDA-Approved Essilor Stellest Lenses Designed to Mitigate Myopia Progression